Introduction
Coronary artery disease (CAD) is projected to remain the leading cause of mortality and morbidity worldwide. Patients with a history of CAD are at higher risk of subsequent adverse cardiovascular events, such as an acute coronary syndrome (ACS). In approximately 75% of all cases, an ACS is caused by rupture or fissure of a vulnerable, lipid rich core-containing plaque in the coronary arteries. 1, 2 While coronary angiography (CAG) is unable to identify such lipid rich core-containing plaques in the coronary artery wall, 3 they can be identified by near-infrared spectroscopy (NIRS), a catheter-based intracoronary imaging technique based on diffuse reflectance spectroscopy. [4] [5] [6] Therefore, NIRS may be useful in identifying patients at increased risk of adverse cardiovascular outcome. [5] [6] [7] The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO) and the Integrated Biomarker Imaging Study 3 (IBIS-3) studies were designed to investigate phenotypes and vulnerability of coronary atherosclerosis as determined by intravascular ultrasound (IVUS) and NIRS. 8, 9 NIRS became available in our cardiac catheterization laboratory during the course of both the ATHEROREMO and IBIS-3 study. 10 In the current study, we performed long-term follow-up of both the ATHEROREMO-NIRS and IBIS-3-NIRS substudies, with the aim to investigate the long-term prognostic value of lipid rich corecontaining plaques as assessed by NIRS in patients with CAD undergoing CAG.
Methods

Study design and population
The current investigation combines the populations of the ATHEROREMO-NIRS and the IBIS-3-NIRS substudies. Both of these studies were conducted at the Erasmus Medical Center, Rotterdam, The Netherlands, and had similar enrolment criteria and baseline study procedures. The study designs and methods of ATHEROREMO-NIRS and IBIS-3-NIRS have been described in detail elsewhere. [8] [9] [10] Briefly, patients undergoing diagnostic CAG or PCI for ACS or stable angina pectoris (SAP) underwent baseline invasive imaging by NIRS and IVUS, and were subsequently followed-up on adverse cardiovascular events. 11, 12 The obtained images were analysed off-line, and findings were not used for patient care. In ATHEROREMO-NIRS, patient management was left to the discretion of the treating physician. In IBIS-3, as per protocol, highdose rosuvastatin was prescribed during the first year after the index event. ATHEROREMO-NIRS enrolled 203 patients between April 2009 and January 2011, and IBIS-3-NIRS enrolled 131 patients between January 2010 and June 2013. Since 48 patients participated in both studies, a total of 286 patients were available. Of these patients, 275 patients had baseline data available on both NIRS and IVUS, and were therefore included in the current analysis. The medical ethics committee of the Erasmus MC approved both the ATHEROREMO-NIRS and IBIS-3-NIRS substudy. These two studies were performed in accordance with the declaration of Helsinki. All patients provided written informed consent for their participation and for compliance with the study protocols, including long-term follow-up. The ATHEROREMO study is registered in ClinicalTrials.gov, number NCT01789411, and the IBIS-3 study is registered in The Netherlands trial register, number NTR2872.
Near-infrared spectroscopy
Subsequent to the standard index CAG, invasive imaging with IVUS and NIRS was performed in a non-culprit coronary artery. The NIRS target segment in this non-culprit coronary artery was required to be at least 40 mm in length and without significant luminal narrowing (<50% stenosis) as assessed by on-line angiography. The study protocol predefined the order of preference for the selection of the non-culprit vessel. 8, 9 The NIRS system included a 3.2-F rapid exchange catheter, a console and a rotation and pullback device (InfraRedx, Burlington, Massachusetts).
Images were acquired by the NIRS catheter that was automatically pulled back at a speed of 0.5 mm/s and 240 rotations per minute in a proximal segment of the non-culprit artery, as described in detail previously. 5, 10 The fraction of yellow pixels obtained from the chemogram, an image map derived from the NIRS measurements, was multiplied by 1000 to compute the lipid core burden index (LCBI). Therefore, the 4 mm long segment with the maximum LCBI (MaxLCBI 4mm ) ranged from 0 to 1000 representing the percentage of lipid core in the investigated segment. 6 Moreover, the 10 mm long segment with the maximum LCBI (MaxLCBI 10mm ) was quantified, and the same was done for the region of interest (LCBI ROI ) of the investigated segment. NIRS data were analysed off-line by an independent corelab (Cardialysis, Rotterdam, The Netherlands) blinded to all other patient and outcome data.
Intravascular ultrasound
After the standard index CAG, the non-culprit segment was first examined by IVUS. IVUS images were acquired by the Volcano Eagle Eye Gold IVUS catheter (20 MHz). 8 Analyses of the IVUS gray-scale data were performed using the pcVH 2.1 and qVH software (Volcano Corp., San Diego, CA, USA). Segmental plaque burden was defined as the plaque and media cross-sectional area divided by the external elastic membrane cross-sectional area. 8 IVUS gray-scale data were also analysed off-line.
Study endpoints
The primary endpoint consisted of major adverse cardiac events (MACE), defined as the composite of all-cause death, non-fatal ACS, or unplanned coronary revascularization during long-term follow-up. A secondary analysis was performed on the composite endpoint of cardiac death, non-fatal ACS, or unplanned revascularization. Furthermore, additional analyses were performed on these two endpoints after exclusion of definite target lesion-related events, as well as after exclusion of adverse events related to the NIRS-imaged coronary segment. Follow-up was conducted in January 2015. Vital status of the patients was obtained from municipal civil registries. Follow-up questionnaires were subsequently sent to all living patients as a first screening method for identifying possible adverse events. Thereafter, hospital discharge letters were obtained if any hospitalization or possible event was reported. In patients who did not return the questionnaire, the local hospital records were investigated for possible events. Cause of death was obtained from hospital records, autopsy reports or general practitioners notes.
MACE were adjudicated based on original source data by a clinical events committee blinded to patient characteristics and NIRS and IVUS data. In accordance with the guidelines of the European Society of Cardiology, non-fatal ACS was defined as the clinical diagnosis of STsegment Elevation Myocardial Infarction (STEMI), non-STEMI (NSTEMI), or unstable angina pectoris. 13, 14 Unplanned coronary revascularization was defined as any PCI or coronary artery bypass grafting (CABG) that was not planned after the index angiography and enrolment in the study. Cardiac death was defined as any death due to proximate cardiac cause, unwitnessed death or death of unknown cause. Furthermore, the clinical event committee adjudicated whether the cardiac events were related to the target lesion that was treated during the index procedure, as well as whether the events were related to the coronary artery segment that was imaged at baseline. Patients that were lost to follow-up were censored at the date of last contact. The first event was considered in case a patient had multiple events. The Kaplan-Meier method was used to estimate cumulative event rate. All subsequent analyses were performed for each of the three LCBI variables. The log-rank test was used to compare cumulative event rates between quartiles of the LCBI variables and pairwise comparisons were performed when the overall log-rank test showed statistical significant differences.
Statistical analysis
The association between LCBI and the long-term incidence of study endpoints was analysed by Cox proportional hazard regression analyses. Furthermore, to evaluate whether the association between LCBI and log(hazard) was linear enough to fit as a single degree of freedom regression term, a spline was inserted in each full Cox proportional hazard regression model and visual inspection of the estimated relation was performed. No evidence was found for non-linearity with respect to MaxLCBI 4mm , whereas findings with respect to MaxLCBI 10mm and LCBI ROI were borderline significant. Visual inspection of the estimated relation showed that categorization of LCBI in quartiles resulted in an acceptable piece-wise linearity for all endpoints. For Cox regression analyses, consecutively, unadjusted models and multivariable models containing clinical characteristics and IVUS derived plaque burden were used. Potential confounders were chosen based on existing literature. The multivariable models contained the following potential confounders: age, gender, indication for index CAG (ACS or SAP), diabetes mellitus, history of cerebrovascular accident, history of peripheral artery disease, and IVUS derived segmental plaque burden. Hazard ratios (HRs) were reported with 95% confidence intervals (CIs). Although this study did not aim to develop a prognostic model per se, a C-index was reported for each multivariable model to provide some indication of the prognostic value of continuous LCBI in addition to clinical risk factors and plaque burden.
All statistical tests were two-tailed and P-values <0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS statistics version 21.0 (IBM Corp., Armonk, New York).
Results
Baseline characteristics
Mean age of the patients was 62.5 years and 76.7% were men ( Table 1) 
Incidence of primary endpoint
Median follow-up time was 4.1 (IQR: 3.2-4.5) years. The follow-up questionnaire assessing the occurrence of MACE was completed by 90% of the patients. The primary composite endpoint of all-cause death, non-fatal ACS or unplanned revascularization occurred in 79 patients (28.7%). All-cause death occurred in 20 patients, non-fatal ACS in 40 patients and unplanned revascularization in 62 patients. The composite endpoint of cardiac death, non-fatal ACS or unplanned revascularization occurred in 70 patients (25.5%).
Association between LCBI and MACE
The cumulative distribution of the MaxLCBI 4mm values in patients with and without MACE shows that patients with MACE had higher MaxLCBI 4mm values as compared with those without MACE ( Figure 1) .
Quartiles of MaxLCBI 4mm , MaxLCBI 10mm , and LCBI ROI , and cumulative MACE incidence were pairwise compared. Pairwise comparisons consequently showed that patients in the third and fourth quartiles had significantly higher event rates compared with those in the first quartile ( Figure 2 The C-indices indicate that NIRS-derived LCBI has prognostic value in addition to clinical risk factors and IVUS-derived plaque burden, with C-indices of the models with only covariates ranging from 0.607 to 0.617 and C-indices of the multivariable models including continuous LCBI ranging from 0.674 to 0.704 (Table 3) .
Association between LCBI and the composite endpoint of cardiac death, non-fatal ACS or unplanned revascularization
The cumulative incidence of the composite of cardiac death, non-fatal ACS or unplanned revascularization was higher in patients in the second (25.0%), third (31.3%), and fourth (35.7%) quartile of MaxLCBI 4mm as compared with those in the first (10.3%) quartile of MaxLCBI 4mm (log-rank pairwise comparisons P = 0.031, P = 0.002, and P = <0.001, respectively, Figure 3 ). The second, third, and fourth quartiles of MaxLCBI 4mm were significantly associated with the composite of cardiac death, non-fatal ACS, or unplanned revascularization after adjustment for clinical characteristics and IVUS-derived plaque burden in the multivariable model ( Table 4) . A similar significant association was observed for MaxLCBI 4mm as a continuous variable ( Table 5) . This association persisted after exclusion of target lesion-related events and after exclusion of events related to the imaged segment ( Table 5 ). In general, the associations observed between MaxLCBI 4mm , MaxLCBI 10mm , and LCBI ROI and the occurrence of adverse events were stronger and more significant when the composite endpoint included cardiac death instead of allcause mortality ( Tables 2-5) .
Discussion
This study investigated the association between lipid rich corecontaining plaques as identified by NIRS in a non-culprit coronary artery and the occurrence of adverse cardiac events during longterm follow-up in patients undergoing CAG. This study showed that LCBI values were significantly and independently associated with the incidence of adverse cardiac outcome in patients with CAD over 4 years of follow-up. To the best of our knowledge, this is the first study to investigate the association between LCBI in a non-culprit coronary artery and adverse cardiac outcome over 4 years of followup, which represents the longest follow-up period so far reported.
Studies on the relationship between LCBI and (long-term) followup are scarce. Recently, the COLOR study demonstrated that the MaxLCBI 4mm obtained prior to stenting in a culprit coronary segment was not associated with culprit-related MACE during 2 years of follow-up. 15 Our study provides new evidence on the prognostic value of NIRS, since we demonstrated that NIRS is predictive of MACE on the long-term by identifying high-risk lipid rich core-containing plaques in a non-culprit artery. The upcoming Lipid Rich Plaque (LRP) and PROSPECT-2 studies are also investigating the ability of NIRSderived LCBI in non-culprit coronary arteries to predict adverse cardiovascular outcome during 2-year follow-up. This study extends our previous 1-year follow-up data of the ATHEROREMO-NIRS study, which investigated the 1-year prognostic value of NIRS in that cohort and showed that high LCBI values were associated with an increased incidence of MACE. 10 The current study demonstrated that these results persist over a period of 4 years, suggesting that the increased risk at 1-year was not due to chance and LCBI of a non-culprit artery also has prognostic value beyond 1-year after the index CAG. As compared with the 1-year follow-up, the current study was conducted over a longer follow-up period, had a larger sample size and, consequently, a larger number of endpoints. The latter allowed us to investigate the associations between continuous LCBI values, as well as quartiles of LCBI, and adverse cardiac outcome instead of using a median split for LCBI. These analyses showed a significant and independent continuous relationship between higher LCBI values in a non-culprit coronary artery and adverse cardiac outcome. Importantly, this relationship persisted, and remained essentially unchanged, when target-lesion related adverse cardiac events (TLR) were excluded from the study endpoint, as well as when adverse events related to the imaged coronary segment were excluded. This indicates that LCBI values obtained in a non-culprit coronary artery segment are associated with adverse cardiac events throughout the entire coronary tree. As such, this finding supports the hypothesis that NIRS imaging in a nonculprit coronary artery segment may reflect vulnerability of the entire coronary tree. 8, 16 Previously, the ATHEROREMO-IVUS study demonstrated that IVUS-derived imaging parameters were predictive of MACE. For this reason, we included IVUS-derived plaque burden in the multivariable model to evaluate the independent prognostic value of NIRS. Given that progression of coronary atherosclerosis depends on multiple factors that are cumulative, interactive and non-linear, a combination of these two imaging techniques is likely to result in a higher predictive value.
Other studies used NIRS to investigate the effect of antiatherosclerotic therapy on the amount of lipid core-containing plaques. The YELLOW study demonstrated that patients with multivessel CAD treated for 6 to 8 weeks with rosuvastatin showed a reduction of lipid core in obstructive arteries. 17 The IBIS-3 study
showed that high-dose rosuvastatin resulted in a neutral effect on lipid rich core-containing plaques as determined by NIRS. 18 Recently, it was shown that addition of a PCSK9-inhibitor to stable statin therapy resulted in a greater decrease of plaque burden as assessed by IVUS. 19 NIRS has improved ability to identify lipid core-containing coronary plaques as compared with other invasive imaging modalities including IVUS, since NIRS is able to distinguish cholesterol from other tissue characteristics. 6 In this context, NIRS may be used to select patients with high LCBI values in future research to measure the effect of anti-atherosclerotic therapy on lipid rich core-containing plaques in the coronary artery wall and assess its association with adverse cardiac outcome. Ultimately, this may result in improved risk stratification and management of patients with CAD.
Limitations
Several study limitations warrant consideration. First, our study population also comprised patients from IBIS-3, who received high doses of rosuvastatin after the index procedure. This may also in part have affected the effect estimates. However, a post-hoc analysis did not display significant effect modification according to study. Second, the follow-up questionnaire was completed by 90% of the patients. Although for the majority of the remaining patients, followup information was retrieved from our local hospital records, we cannot fully exclude the possibility that loss to follow-up was in part selective. However, a post-hoc analysis of clinical and NIRS characteristics of the non-responders as compared with those of the responders did not show any differences that indicated selective loss to follow-up.
Third, the sample size of this single-centre study was relatively small. Nevertheless, our study had a large number of endpoints. This allowed us to analyse LCBI as quartiles and as a continuous variable, as well as to investigate the association with adverse cardiac outcome after exclusion of target lesion-related and imaged segment-related events. When the results of the LRP and PROSPECT-2 studies become available, a meta-analysis may provide more precise effect estimates. Furthermore, as the current study population comprises a broad spectrum of CAD patients, the results are expected to apply to a broad population of CAD patients.
Conclusions
In conclusion, this study demonstrates for the first time that LCBI, as assessed by NIRS in one non-culprit coronary artery segment, predicts adverse cardiac outcome, independent of clinical characteristics and IVUS, during long-term follow-up over 4 years in patients referred for CAG because of ACS or SAP.
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